Duality Biotherapeutics (FRA:4ZB) Total Tax Payable: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Total Tax Payable?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Total Tax Payable is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Duality Biotherapeutics's Total Tax Payable for the quarter that ended in Jun. 2026 was €0.0 Mil.

Duality Biotherapeutics's quarterly Total Tax Payable declined from Jun. 2025 (€0.2 Mil) to Dec. 2025 (€0.0 Mil) but then stayed the same from Dec. 2025 (€0.0 Mil) to Jun. 2026 (€0.0 Mil).

Duality Biotherapeutics's annual Total Tax Payable increased from Dec. 2023 (€0.1 Mil) to Dec. 2024 (€0.2 Mil) but then declined from Dec. 2024 (€0.2 Mil) to Dec. 2025 (€0.0 Mil).

Duality Biotherapeutics Total Tax Payable Related Terms

Duality Biotherapeutics Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Total Tax Payable Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Tax Payable
0.09 0.12 0.23 0.00

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Total Tax Payable 0.18 0.00 0.00
FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of €0.0 Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Total Tax Payable of €0.0 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Total Tax Payable too high?
Duality Biotherapeutics' current Total Tax Payable is €0.0 Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Total Tax Payable compare to VRTX and REGN?
Duality Biotherapeutics' Total Tax Payable of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Total Tax Payable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Total Tax Payable of €0.0 Mil. The current Total Tax Payable is €0.0 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Total Tax Payable is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price